Pluri Signed $4.2M Contract With US National Institutes Of Health To Advance Development Of Its PLX-R18
Portfolio Pulse from Benzinga Newsdesk
Pluri has signed a $4.2M contract with the US National Institutes Of Health to advance the development of its PLX-R18 cell therapy. The therapy is a potential treatment for Hematopoietic Acute Radiation Syndrome (H-ARS), a deadly disease resulting from nuclear disasters and radiation exposure. Pluri will collaborate with the U.S. Department of Defense's Armed Forces Radiobiology Research Institute (AFRRI)/Uniformed Services University of Health Sciences (USUHS) in Maryland.

July 11, 2023 | 6:28 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Pluri's new contract with the US National Institutes Of Health and collaboration with AFRRI/USUHS could potentially boost the development of its PLX-R18 cell therapy, potentially leading to increased investor interest.
The contract and collaboration could accelerate the development of Pluri's PLX-R18 cell therapy, potentially leading to increased investor interest and a positive impact on the company's stock price.
CONFIDENCE 85
IMPORTANCE 80
RELEVANCE 100